Collaborations

Collaborations with Life Sciences companies and academic organizations are a central component of our business strategy.

Collaborations with life sciences companies

Algonomics initiated several collaborations regarding vaccine development, therapeutic peptide discovery, and the immunoprofiling of therapeutic proteins. These collaborations include:

	4-Antibody AG: 4-Antibody AG has access to Epibase® technology for T-cell epitope identification.
	Ablynx NV: Ablynx and Algonomics have a research collaboration regarding the selection of antibody-derived peptide leads.
	Alligator Bioscience: Alligator Bioscience AB addresses immunogenicity with Epibase® to maximally reduce immunogenicity upon optimization of protein therapeutics with Alligator's proprietary ssDNA recombination technology FIND®.
	BAC: BAC bv has access to Algonomics' structural bioinformatics platform.
	Bayer CropScience: Algonomics has entered into a research collaboration with Bayer CropScience involving protein engineering and enzyme substrate modification.
	Bayer HealthCare: Bayer HealthCare AG has access to Epibase® technology for T-cell epitope profiling.
	CAT: Cambridge Antibody Technology Ltd. has access to Epibase® technology for T-cell epitope profiling.
	Evogenix Ltd.: Evogenix Ltd. has access to Epibase® technology for T-cell epitope identification. Peptech Ltd.: Peptech has access to Epibase® technology for T-cell epitope identification.
	Genmab AS: Algonomics NV entered into an agreement granting Genmab A/S access to the Epibase® platform for T-cell epitope identification.
	GSK Biologicals: GSK Biologicals has access to Epibase® technology for T-cell epitope identification. GSK R&D: GSK Research and Development has access to Epibase® technology for T-cell epitope identification.
	Innogenetics NV: Innogenetics employs the Epibase® platform in the development of an hepatitis C poly-epitope vaccine.
	Kirin Brewery: Kirin Brewery Ltd. has access to Epibase® technology for the immunoprofiling of therapeutic proteins.
	MAT Biopharma: MAT Biopharma SA and Algonomics entered into a research collaboration. Algonomics will employ its structural bioinformatics platform to assist MAT Biopharma in its research related to the structural analysis of its antibody leads.
	Maxygen: Maxygen Inc. has access to Epibase® technology for T-cell epitope identification.
	Pieris AG: Pieris has access to Epibase® technology for T-cell epitope identification.
	ProtAffin Biotechnologie AG: ProtAffin Biotechnologie has access to Epibase® technology for T-cell epitope identification.
	Resistentia Pharmaceuticals AB: Resistentia Pharmaceuticals has access to Epibase® technology for T-cell epitope identification.
	Syntaxin Ltd: Syntaxin has access to Epibase® technology for T-cell epitope identification.
	Tibotec: Algonomics entered into a research collaboration with Tibotec, a subsidary of Johnson & Johnson, involving structural bioinformatics services on undisclosed targets.
	UCB Celltech: UCB Celltech has access to Epibase® technology for T-cell epitope identification.